GSK Can Seize Chance In Anemia After Rivals Rejected But FDA Caution Will Remain

Daprodustat Filing Accepted In US

 
• By Andrew McConaghie
US FDA entrance
Following the rejection of rival candidates from Fibrogen/AstraZeneca and Akebia, GSK is confident its data will be enough to secure approval • Source: Alamy

More from Business

More from Scrip